MX346533B - Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides). - Google Patents

Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).

Info

Publication number
MX346533B
MX346533B MX2013009760A MX2013009760A MX346533B MX 346533 B MX346533 B MX 346533B MX 2013009760 A MX2013009760 A MX 2013009760A MX 2013009760 A MX2013009760 A MX 2013009760A MX 346533 B MX346533 B MX 346533B
Authority
MX
Mexico
Prior art keywords
disease
hyperalgesia
crystalline forms
osteoarthritis
receptor
Prior art date
Application number
MX2013009760A
Other languages
English (en)
Other versions
MX2013009760A (es
Inventor
c blackburn Anthony
Han Sangdon
M Jones Robert
Garrido Montalban Anthony
B Pal Biman
Karyn Rueter Jaimie
Original Assignee
Arena Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc
Publication of MX2013009760A publication Critical patent/MX2013009760A/es
Publication of MX346533B publication Critical patent/MX346533B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a formas cristalinas de ((S)-1-hidroximetil-1,2-dimetil-propil)-amida de ácido (1aS,5aS)-2-(4-oxi-pirazin-2-il)-1a,2,5,5a-tetrahidro-1H-2,3-diaz a-ciclopropa[a}pentalen-4- carboxílico y composiciones farmacéutica de la misma que modulan la actividad del receptor canabinoide CB2 y por lo tanto son útiles en el tratamiento de desórdenes mediados por receptor CB2, por ejemplo, osteoartritis; dolor; hiperalgesia; alodinia; hiperalgesia inflamatoria; hiperalgesia neuropática, nocicepción aguda; osteoporosis; espasticidad asociada con esclerosis múltiple; desórdenes autoinmunes; reacciones alérgicas inflamación de CNS por ejemplo; aterosclerosis; actividad celular inmune no deseada, e inflamación asociada con un desorden seleccionado de: osteoartritis, anafilaxis, enfermedad de Behcet, rechazo de injerto, vasculitis, gota, espondilitis, enfermedad viral, enfermedad bacteriana, lupus, enfermedad inflamatoria intestinal, hepatitis autoinmune y diabetes mellitus tipo 1; degeneración macular relacionada con la edad; tos; leucemia; linfoma; tumores de GNS; cáncer de próstata; enfermedad de Alzheimer; daño inducido por apoplejía; demencia; esclerosis lateral amiotrófica; y enfermedad de Parkinson.
MX2013009760A 2011-02-25 2012-02-24 Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides). MX346533B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US201161448542P 2011-03-02 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (2)

Publication Number Publication Date
MX2013009760A MX2013009760A (es) 2014-06-11
MX346533B true MX346533B (es) 2017-03-14

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009760A MX346533B (es) 2011-02-25 2012-02-24 Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).

Country Status (19)

Country Link
US (4) US9458136B2 (es)
EP (3) EP2678330A1 (es)
JP (1) JP5945554B2 (es)
KR (1) KR102036932B1 (es)
CN (1) CN103608343B (es)
AU (1) AU2012222146B2 (es)
BR (1) BR112013021549B1 (es)
CA (1) CA2827057C (es)
CL (1) CL2013002436A1 (es)
CO (1) CO6852066A2 (es)
DK (1) DK3395812T3 (es)
EA (1) EA035989B1 (es)
ES (1) ES2932441T3 (es)
IL (1) IL227782A (es)
MX (1) MX346533B (es)
MY (1) MY165767A (es)
SG (1) SG192817A1 (es)
WO (1) WO2012116276A1 (es)
ZA (1) ZA201306402B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103539785B (zh) 2009-08-28 2015-09-23 艾尼纳制药公司 大麻素受体调节剂
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
ES2932441T3 (es) 2011-02-25 2023-01-19 Arena Pharm Inc Formas cristalinas y procesos para la preparación de azaciclos condensados (moduladores de los receptores cannabinoides)
CN109970708B (zh) * 2011-02-25 2022-06-21 艾尼纳制药公司 大麻素受体调节剂
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
WO2017180528A1 (en) * 2016-04-10 2017-10-19 Arena Pharmaceuticals, Inc. Methods of treatment with selective cb2 receptor agonists
MA48625A (fr) * 2017-05-08 2020-03-18 Arena Pharm Inc Composés et méthodes de traitement de la douleur viscérale
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
WO2021047581A1 (zh) * 2019-09-12 2021-03-18 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
TW202330496A (zh) 2021-10-05 2023-08-01 美商艾尼納製藥公司 用於製備大麻素受體調節劑之結晶形式及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
YU72201A (sh) 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
JP2005516004A (ja) 2001-12-07 2005-06-02 ヴァージニア コモンウェルス ユニバーシティ 新形成の治療
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
NZ552670A (en) 2004-07-12 2010-02-26 Cadila Healthcare Ltd Tricyclic pyrazole derivatives as cannabinoid receptor modulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
PL1902034T3 (pl) * 2005-06-02 2011-09-30 Glenmark Pharmaceuticals Sa Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania
ES2362369T3 (es) * 2005-06-02 2011-07-04 Glenmark Pharmaceuticals S.A. Nuevos ligandos de receptores de canabinoides, composiciones farmacéuticas que los contienen, y procedimientos para su preparación.
WO2008003665A1 (en) 2006-07-04 2008-01-10 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists bearing a substituted heterocyclic group
CA2664310A1 (en) 2006-09-25 2008-04-03 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
WO2008048914A1 (en) 2006-10-17 2008-04-24 Boehringer Ingelheim International Gmbh Polycyclic compounds which modulate the cb2 receptor
WO2008053341A2 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Bridged bicyclic indazoles as cannabinoid receptor ligands
US8173638B2 (en) 2006-11-21 2012-05-08 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2120938A4 (en) 2006-12-20 2010-12-08 Merck Sharp & Dohme IMIDAZOPYRIDINE ANALOGUE AS CB2 RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES
WO2008079316A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof
US20080214537A1 (en) 2007-03-02 2008-09-04 Cara Therapeutics, Inc. Bridged phenanthridines
JP5185924B2 (ja) 2007-03-16 2013-04-17 京セラ株式会社 誘電体磁器およびコンデンサ
WO2008119694A1 (en) 2007-03-30 2008-10-09 Janssen Pharmaceutica Nv Benzimidazole cannabinoid agonists
WO2008157500A1 (en) 2007-06-17 2008-12-24 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
WO2008157751A2 (en) 2007-06-21 2008-12-24 Cara Therapeutics, Inc. Substituted imidazoheterocycles
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
EP2203171A2 (en) 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
KR101787116B1 (ko) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
US7741350B1 (en) 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
CN103539785B (zh) * 2009-08-28 2015-09-23 艾尼纳制药公司 大麻素受体调节剂
CN109970708B (zh) 2011-02-25 2022-06-21 艾尼纳制药公司 大麻素受体调节剂
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
ES2932441T3 (es) * 2011-02-25 2023-01-19 Arena Pharm Inc Formas cristalinas y procesos para la preparación de azaciclos condensados (moduladores de los receptores cannabinoides)
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators

Also Published As

Publication number Publication date
US20140135345A1 (en) 2014-05-15
EP4166552A1 (en) 2023-04-19
MY165767A (en) 2018-04-23
NZ614787A (en) 2014-08-29
EA201391233A1 (ru) 2014-02-28
US9458136B2 (en) 2016-10-04
EP2678330A1 (en) 2014-01-01
CN103608343A (zh) 2014-02-26
US11560369B2 (en) 2023-01-24
CA2827057C (en) 2022-06-07
AU2012222146A1 (en) 2013-09-19
BR112013021549B1 (pt) 2022-01-11
EP3395812A1 (en) 2018-10-31
AU2012222146B2 (en) 2017-05-11
JP5945554B2 (ja) 2016-07-05
MX2013009760A (es) 2014-06-11
IL227782A0 (en) 2013-09-30
EP3395812B1 (en) 2022-09-28
DK3395812T3 (da) 2022-11-28
EA035989B1 (ru) 2020-09-09
JP2014506602A (ja) 2014-03-17
IL227782A (en) 2017-02-28
ES2932441T3 (es) 2023-01-19
WO2012116276A1 (en) 2012-08-30
US20170144993A1 (en) 2017-05-25
US10183930B2 (en) 2019-01-22
CO6852066A2 (es) 2014-01-30
KR102036932B1 (ko) 2019-10-25
US20190308952A1 (en) 2019-10-10
EP3395812B8 (en) 2022-11-02
CA2827057A1 (en) 2012-08-30
BR112013021549A2 (pt) 2016-11-01
SG192817A1 (en) 2013-09-30
CL2013002436A1 (es) 2014-01-24
US10981895B2 (en) 2021-04-20
ZA201306402B (en) 2022-03-30
CN103608343B (zh) 2019-02-01
US20210380560A1 (en) 2021-12-09
KR20140025353A (ko) 2014-03-04

Similar Documents

Publication Publication Date Title
MX346533B (es) Formas cristalinas y procesos para la preparacion de azaciclos condensados (moduladores de receptores canabinoides).
ZA202205142B (en) Cannabinoid receptor modulators
WO2011075534A3 (en) Purification of isoprene from renewable resources
AU2011343222B2 (en) Novel 7B-hydroxysteroid dehydrogenase mutants and process for the preparation of ursodeoxycholic acid
JP2013533314A5 (es)
MX355126B (es) Compuestos neuroesteroides.
WO2013060614A9 (de) Farbstabile härterzusammensetzungen enthaltend polyisocyanate (cyclo)aliphatischer diisocyanate
BR112012019156A2 (pt) processo para recuperação de etanol
WO2012173659A3 (en) Lignocellulosic hydrolysates as feedstocks for isobutanol fermentation
WO2011139107A3 (en) Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and phamaceutical composition comprising the same
BR112012019406A2 (pt) processo para purificacao de um produto de etanol bruto
MX347947B (es) Metodo y sistema para preparar cloruro de hidrogeno de alta pureza.
WO2012102896A3 (en) Processes and systems for enzymatically isolating lignin and other bioproducts from herbaceous plants
WO2012104244A8 (de) Verfahren zur fermentativen herstellung von 2,3-butandiol
MX2012004559A (es) Metodos y sistemas para tratamiento farmacogenomico de condiciones cardiovasculares.
IN2014MN01003A (es)
NZ703093A (en) Purification of iduronate-2-sulfatase
WO2009053446A3 (en) Pregabalin intermediates and process for preparing them and pregabalin
AU2007307111A1 (en) High-purity large-scale preparation of stannsoporfin
WO2010066680A3 (de) Verfahren zur abtrennung metallischer verunreinigungen
MX2014005561A (es) Suavizante de telas.
WO2010090536A3 (en) Plant transformation using dna minicircles
WO2011049334A3 (ko) 식물병에 대해 저항성을 증진시키는 ＯｓＬＲＰ 유전자 및 이의 용도
IL231490B (en) A viral vector containing a plant DNA sequence (codon-optimized) and a method for the temporary production of cholinesterase using this vector
WO2013072592A3 (fr) Épaississants non ioniques associatifs contenant des alkyls cyclohexylols alkoxyles, leurs utilisations et formulations les contenant

Legal Events

Date Code Title Description
FG Grant or registration